The disclosure provides a method of using blood or fractions thereof, e.g., serum, obtained from a mammal subjected to liver surgery, for example, obtained following a partial hepatectomy, to increase the engraftment, proliferation and/or functionality of cells on a biocompatible scaffold.

Compositions are provided herein comprising a coacervate of a polycationic polymer, a polyanionic polymer, and platelet-rich plasma and/or serum, or a fraction or concentrate thereof. The composition is useful in wound healing. Compositions also are provided that comprise a hydrogel comprising TIMP-3; and a complex of a polycationic polymer, a polyanionic polymer, FGF-2 and SDF-1α embedded in the hydrogel, which is useful in treating a myocardial infarction.

The present disclosure provides a method for obtaining osteoblast cell-mixture which can be used for transplantation of osteoblast cells in a subject. The present disclosure further discloses a method for delivering osteoblast cells into a subject. The method for obtaining osteoblast cell-mixture as disclosed herein is devoid of any additives like calcium chloride and aprotinin. The method for delivering osteoblast cells as disclosed herein provides bone regeneration in the subject.

The invention relates to medical biotechnology, medicine, traumatology, orthopedics, dentistry, and orthodontics. A method is proposed for producing a biological matrix intended for the repairing of bone tissue defects; said method may include a plurality of consecutive stages, such as pre-treating biological material, coarse filtering and fractionating, fine filtering and extracting, delipidizing, fermenting, demineralizing, and sterilizing in supercritical fluid. The resulting bioresorbable biological matrix is characterized by increased osteo- and biointegration, an optimal biodegradation rate, high biocompatibility, an absence of recipient immunoreactivity, high osteoconduction capacity, and pronounced osteogenic potential in osteosynthesis and bone grafting. The matrix consists of ossein, hydroxyapatite and/or calcium phosphate, wherein the ossein is in native unreduced form with its three-dimensional structure completely intact, the hydroxyapatite and calcium phosphate are in native amorphous form, and the matrix itself, from which cellular debris, foreign lipids, nucleic acids, and immunogens have been removed, contains residual amounts of bone morphogenetic proteins and is impregnated with vesicular phosphatidylcholine and/or cholesterol containing gelatin (hydrolyzed collagen), and/or bone atelocollagen, and/or poly-(ε-caprolactone) and additionally containing biologically active substances (including bioactive peptides and growth factors).

A device for treating an artificial bone implant with blood, the device comprising: a container configured to accommodate an artificial bone implant and be filled with blood, wherein the container comprises an opening and a cover configured to cover the opening of the container. Additional embodiments of the device and methods for using the same are disclosed herein.

The present invention relates to porous composite materials and objects such as 3D scaffolds, in particular to bioactive and bioresorbable scaffolds that can be transformed at body temperature.

A platelet-rich fibrin (PRF) three-dimensional, adhesive, biocompatible and biodegradable scaffold and/or membrane is obtained by collecting a blood sample, followed by centrifugation of the blood sample to obtain a platelet-rich fibrin clot and an exudate followed by compressing platelet-rich fibrin clot to extract the exudate until the final product being a platelet-rich fibrin three-dimensional, adhesive, biocompatible and biodegradable scaffold is obtained. A hyper-acute serum is obtained by collecting a blood sample, followed by centrifugation of said blood sample to obtain a platelet-rich fibrin clot and an exudate followed by compressing platelet-rich fibrin clot to obtain the membrane and extract the exudate being the final product hyper-acute serum. A process for the preparation of a platelet-rich fibrin three-dimensional, adhesive, biocompatible and biodegradable scaffold and/or membrane and a hyper-acute serum is also provided. A method for the treatment of inguinal hernia in a patient in need thereof is also provided.

Provided is a method for making a biotransplant, comprising introducing autologous fibroblasts isolated from an oral mucosa of a patient into a platelet-rich fibrin (PRF) membrane using linear retrograde needle injection, where a needle is inserted into a thickness of the PRF membrane and a first puncture is made and then a series of punctures are made that are linearly aligned or arrayed with the first puncture and are spaced at a predetermined distance from a prior puncture. A method of treatment of a periodontal tissue and a biotransplant comprising a PRF membrane and autologous fibroblasts are also provided.

The invention relates to hardenable ceramic bone substitute compositions having improved setting, powders for such compositions and methods for their manufacture and use in medical treatment. More specifically the invention relates to hardenable bone substitute powder and hardenable bone substitute paste with improved setting properties, comprising calcium sulfate and heat-treated hydroxyapatite (passivated HA), which bone substitute is suitable for treatment of disorders of supportive tissue such as bone loss, bone fracture, bone trauma and osteomyelitis.

The present disclosure is drawn to compositions and methods of making and using lyophilized platelet lysates. Specifically, a method of preparing a composition suitable for therapeutic use or as a culture medium can comprise steps of concentrating platelets from a platelet source to form a platelet rich portion of the platelet source, and lysing the platelets in the platelet rich portion to form a plurality of lysates. An additional step includes lyophilizing the lysates to form lyophilized platelet lysates in a composition with released concentrations of available growth factors, cytokines, and chemokines. In one example, at 30%, by platelet count, of platelets from a platelet source can be lysed using this process.